Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Polyphor Ltd.

www.polyphor.com

Latest From Polyphor Ltd.

Roche Goes Back To Nature With Warp Drive Antibiotic Pact

The Swiss major is paying up to $387m to get access to potential natural antibiotics that have not been analyzed previously, 'owing to historical technology limitations.'

Infectious Diseases Research & Development

Polyphor Pursues Promise Of Inhaled Antibiotics To Tackle Lung Infections

An IMI-backed consortium is developing inhaled formulations of the privately held Swiss company's murepavadin and Novartis's tobramycin to reduce infections suffered by bronchiectasis and cystic fibrosis patients.

Respiratory Infectious Diseases

Antibiotic Spring? Regulatory Incentives Spur Activity – And Maybe Medical Advances

Regulatory incentives have been successful at attracting developers to antibiotic R&D, but significant medical advances have stubbornly remained rare. Now the pipeline has produced the first novel antibiotic to receive breakthrough status from US FDA and some Phase III trials are raising the efficacy bar to superiority.

Clinical Trials Review Pathway

Antibiotic Pipeline Profile: Narrowing The Spectrum Of Drug Activity

Development is most advanced in C. difficile infection, but US FDA's exploration of pathways to expedite single pathogen treatments could spur earlier-stage QIDP projects targeting Staphylococcus and Pseudomonas species.

Infectious Diseases Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Polyphor Ltd.
  • Senior Management
  • Giacomo Di Nepi, CEO
    Kalina Scott, CFO
    Daniel Obrecht, PhD, CSO
    Helmut Kessmann, PhD, Head, Bus. Dev.
    Debra Barker, MD, CMO & Chief Dev. Officer
  • Contact Info
  • Polyphor Ltd.
    Phone: (41) 61 567 16 00
    Hegenheimermattweg 125
    Allschwil, CH-4123
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register